

2nd JHAAN meeting, 21 June 2021

TOUR DE TABLE - EMCDDA

Institutional

1. The new EU Drugs Action Plan 2021-2025 was approved by the Council in June with important work for the JHA agencies in security and health areas. There is an emphasis of the Action Plan on key vulnerable groups at risk of drug use and related problems incl. Women, migrants, homeless people. EMCDDA is playing an essential role in implementing some of the actions and providing epidemiological information to document the progress.
2. The EMCDDA is waiting for the opening of the new mandate, which hopefully brings some additional resources and allows the agency to implement new tasks.

Analytical work

1. Launch of the EMCDDA flagship report - European Drug report 2021 took place on 9 June - [European Drug Report 2021 | www.emcdda.europa.eu](http://www.emcdda.europa.eu)
2. A report on new benzodiazepines which highlights public health risks and increasing availability of 'designer benzodiazepines' in Europe [New report highlights public health risks and increasing availability of 'designer benzodiazepines' in Europe | www.emcdda.europa.eu](http://www.emcdda.europa.eu)
3. New products updating on the situation of drug use and market in EU and neighbouring countries [COVID-19 and drugs | www.emcdda.europa.eu](http://www.emcdda.europa.eu)

Collaboration with JHA agencies

1. EMCDDA -CEPOL on the future use of the online learning platform by the EMCDDA
2. EMCDDA - EASO on addressing drug use problems and responses in reception facilities
3. EMCDDA - Europol and other JHA partners through regular work of the Innovation Hub; incl quick wins with JRC, EMCDDA and Europol on developing a darknet monitoring tool